Lexicon Pharmaceuticals | LXRX - Gross Profit On Sales


Lexicon Pharmaceuticals reported $5.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Illumina USD 770M 49M Jun/2026
Insmed USD 356.19M 99.73M Jun/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 18.55B 1.31B Jun/2026
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 11.24M 19.87M Mar/2026
MannKind USD 7.77M 60.56M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Moderna USD -566M 792M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024